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Abstract
Background—Seasonality in human papillomavirus (HPV) vaccination could have a large 
impact on national cancer prevention efforts. We hypothesized that uptake of HPV vaccine and 
other adolescent vaccines in the United States would be highest in the summer.
Methods—Data came from healthcare provider-verified vaccination records for 70,144 
adolescents (ages 13–17) from the 2008–2012 versions of the National Immunization Survey-
Teen. Using the Edwards method for testing annual trends, we examined seasonal patterns in 
uptake of HPV and other recommended adolescent vaccines (tetanus, diphtheria, and pertussis 
(Tdap) booster and meningococcal vaccine). HPV vaccine initiation (receipt of the first of the 
three-dose series) data were for female adolescents.
Results—Uptake for HPV and other adolescent vaccines peaked in the summer across years and 
states (all p<.001). Uptake was 5 times as frequent at the peak as at the trough for HPV vaccine, 
and HPV vaccine initiation was highest in June, July, and August (percent of doses delivered in 
these months: 38.7%). The same pattern existed for Tdap booster and meningococcal vaccine. 
Concomitant (same-day) vaccination of HPV vaccine with other adolescent vaccines also 
demonstrated summer peaks each year nationally (all p<.001).
Conclusion—Uptake of adolescent vaccines increased dramatically in summer months. These 
summer peaks are an important opportunity for interventions focused on concomitant vaccination.
Impact—The potential cancer prevention impact of HPV vaccination programs could be 
increased, for example, by delivering messages about concomitant vaccination during the summer, 
when adolescents and their parents might be most open to them.
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Introduction
Human papillomavirus (HPV) vaccination is a potent tool for preventing several cancers, 
including cervical, anal, vulvar, vaginal and likely oropharyngeal cancers (1), but 
vaccination coverage is sub-optimal (2). In the United States, the Healthy People 2020 goal 
is for 80% of 13- to 15-year-old adolescents to have received the three-dose HPV vaccine, 
as well as two other adolescent vaccines: tetanus, diphtheria, and pertussis (Tdap) booster 
and meningococcal vaccine (3). Coverage for Tdap booster has surpassed that goal, and 
meningococcal vaccine is quickly approaching it (2,4). However, only 28% of females and 
7% of males in this age group had received the entire three-dose HPV vaccine series as of 
2012 (4). Improving these low rates of HPV vaccination could have a tremendous impact on 
population health. Achieving 80% coverage with HPV vaccination could prevent an 
additional 53,000 cases of cervical cancer over the lifetime of females who are now age 12 
or younger (5). For this reason, national organizations including the Centers for Disease 
Control and Prevention (CDC), the National Cancer Institute, and the President’s Cancer 
Panel have prioritized increasing HPV vaccination (e.g., 3,5,6).
A highly promising way to increase HPV vaccination coverage is through concomitant 
administration of HPV vaccines with Tdap boosters or meningococcal vaccines, also called 
“same day” or “bundled” vaccination (1,7). Concomitant vaccination is an effective and safe 
practice (7–10) that CDC endorses (1). A recent study by Stokley and colleagues (11) 
demonstrated that, if all adolescent girls born in 2000 who received another vaccine had 
concomitantly received HPV vaccines, coverage for the latter vaccines among this group 
would have increased from 47% to 91%. However, very few studies have investigated 
concomitant vaccination.
Cancer prevention efforts focused on improving coverage with HPV vaccine and national 
efforts focused on improving coverage with the entire adolescent vaccine platform (Tdap 
booster, meningococcal, and HPV vaccines) have not considered seasonal peaks in 
administration. These peaks may be especially pertinent in the United States, which has an 
opportunistic vaccination program and school entry requirements in some states (12). 
Seasonal peaks may arise due to parents seeking to comply with vaccination school entry 
requirements (13) before the school year begins, among other factors. Indeed, adolescent 
vaccination rates in New York City and several states show preliminary evidence of summer 
peaks (14,15), but no studies that we are aware of have examined seasonality on a national 
level or for concomitant vaccination. In the same way that retailers focus promotional efforts 
for some products around holidays to maximize impact, identifying summer peaks in 
adolescent vaccination could highlight times when quality improvement or promotional 
programs may have higher impact on coverage, an especially important consideration for 
HPV vaccination (16,17). We sought to establish whether summer peaks exist in adolescent 
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vaccination in the U.S. to support efforts to address low HPV vaccination coverage. These 
peaks could affect clinical practice, timing of public health programs, and timing of 
promotional efforts in regards to improving HPV vaccination and cancer prevention.
Materials and Methods
Data source
Data came from the 2008–2012 versions of the National Immunization Survey (NIS) – Teen 
conducted by the CDC (18). NIS-Teen is a two-part survey consisting of telephone 
interviews administered to a national probability sample of caregivers of 13- to 17-year-old 
adolescents (hereafter referred to as “parents”) and questionnaires mailed to adolescents’ 
healthcare providers. In 2008–2010, NIS-Teen staff contacted parents through landline 
numbers, and in 2011–2012, staff also contacted parents through cell phone numbers.
Each year, NIS-Teen collected provider-verified vaccination data for about 20,000 
adolescents living in the 50 states and Washington D.C. (hereafter referred to collectively as 
“states”), for a cumulative total of 99,921 adolescents (18). Because we were interested in 
dates of adolescent vaccination, which is conditional on receiving at least one vaccine, we 
excluded participants whose providers reported that they had not received any adolescent 
vaccine (n=21,574). In addition, we excluded participants who had received at least one 
vaccine, but their providers reported that administration fell outside of the study period 
(2007 to 2012) (n=8,203), for a final analytic sample of 70,144 adolescents. NIS-Teen staff 
calculated sampling weights for each participant with provider-verified data to account for 
non-equal probability of selection.
Data collection for NIS-Teen was approved by the National Center for Health Statistics 
(NCHS) Research Ethics Review Board. Analysis of de-identified data from the survey is 
exempt from the federal regulations for the protection of human research participants. 
Analysis of restricted data through the NCHS Research Data Center is also approved by the 
NCHS Ethics Review Board. The University of North Carolina Institutional Review Board 
exempted our study from review.
Measures
Healthcare providers reported whether adolescents received HPV vaccine, Tdap booster, and 
meningococcal vaccine, and, if so, the month, date, and year of administration. Although 
data collection took place beginning in 2008, we included instances of vaccination that 
occurred on or after January 1, 2007 in this analysis, because providers could report 
vaccinations that took place up to the date of the parent telephone interviews. We analyzed 
HPV vaccine initiation (receipt of the first of the three-dose series) only among female 
adolescents, because the CDC did not introduce a recommendation for routine 
administration to male adolescents until 2011 (19). We coded participants as receiving 
vaccines concomitantly if providers reported administration of two or more vaccines on the 
same day (7). Thus, we captured whether adolescents concomitantly received four possible 
combinations of vaccines: (a) HPV vaccine and Tdap booster; (b) HPV and meningococcal 
vaccines; (c) Tdap booster and meningococcal vaccine; and (d) HPV vaccine, Tdap booster, 
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and meningococcal vaccine (“all three”). State of residence and demographic characteristics 
came from parental report in the telephone interview.
Data Analysis
Data preparation—We combined data from the 2008–2012 versions of NIS-Teen using 
NCHS’s recommended procedures that include creating new weighting variables (18). Then, 
we categorized participants according to the month and year in which they received vaccines 
and generated weighted estimates of the total number of vaccines administered in each 
month of the study period. We standardized the length of each month by dividing the 
monthly vaccination totals by the number of days in the month and multiplying by 30. This 
approach may be unnecessary when analyzing large samples (20), but some researchers have 
noted the value of standardization to remove the influence of month length from studies of 
seasonality (21,22). For analyses that aggregated vaccination data from multiple years, we 
weighted each year’s observations so that years contributed equally.
To create figures depicting vaccination peaks, we put the number of people receiving 
vaccines each month on a common metric, following recommendations by Rau and others 
(20,21,23). We calculated the number of people who received particular vaccines each 
month and scaled the data so that the yearly total was 1,200. Any month with a scaled 
vaccination total exceeding 100 contained greater vaccination than would be expected if 
vaccination were randomly distributed over time, and any month with a scaled vaccination 
total of less than 100 contained less vaccination than expected. This approach facilitates 
descriptive comparison of peaks between geographic units with different population sizes. 
As a supplementary analysis, we created figures depicting Tdap booster and meningococcal 
vaccination peaks stratified by adolescent sex in order to examine comparability with the 
HPV vaccination peaks for female adolescents only. Note that the inferential procedures 
used the month- and year-standardized data (described above), not these scaled observations.
Inferential analysis—We examined seasonal peaks in the U.S. overall and within each 
state for all study years combined, and then for the U.S. within each study year. These three 
approaches allowed us to check for consistency of cyclical patterns across geography and 
time. We performed these calculations separately for HPV vaccine, Tdap booster, and 
meningococcal vaccine, and for each of the concomitant vaccination outcomes. Small 
sample sizes precluded generating estimates for each study year separately within states; for 
concomitant vaccination within states; and for 2012, the final study year, separately from the 
preceding years.
To test the statistical significance of seasonal peaks, we used the Edwards method (20,21), 
the most commonly used analytic approach in seasonality research (21). Briefly, the 
Edwards method involves fitting a harmonic sine curve with one peak and one trough to the 
observed monthly data. (Before implementing these methods, we verified with visual 
inspection that the data did not follow a qualitatively different form, e.g., bimodal, which 
would require different analytic tools.) Edwards T statistic, which measures how far the 
fitted curve differs from non-seasonality (a flat line), follows a chi-square distribution with 
two degrees of freedom. The ratio of highest to lowest (RHL) incidence examines the 
Moss et al. Page 4
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
amplitude of the fitted curve to describe the relative increase in the outcome at the cycle’s 
maximum (its peak) compared to its minimum (its trough) (20,21). Previous public health 
studies have used the Edwards method to assess cyclical patterns in outcomes, such as 
cardiovascular disease, suicide, and malaria (24–26). For each vaccination outcome in the 
current study, we fitted a sine curve to the observed data and calculated the resulting T 
statistic. In addition, we calculated the RHL to summarize the magnitude of the peaks.
All analyses were conducted in SAS version 9.2 (Cary, NC). Statistical tests used a two-
tailed p value of .05. Analyses incorporated survey weights to account for non-equal 
probability of selection.
Results
The 70,144 vaccinated adolescents were nearly evenly distributed by sex and age (Table 1). 
Most adolescents were non-Hispanic white (57.2%), had private health insurance (60.7%), 
and had a preventive healthcare visit in the last year (87.5%). The majority of adolescents 
lived in metropolitan areas (85.7%) and in households above the poverty level (74.3%).
About 48% of female adolescents initiated HPV vaccine vaccination between 2008 and 
2012 (Table 2). Among female and male adolescents, coverage was 66% for Tdap booster 
and 59% for meningococcal vaccination. Concomitant HPV vaccination was far less 
frequent: among females, 16% received HPV vaccine concomitantly with Tdap booster, 
22% concomitantly with meningococcal vaccine, and 8% received all three vaccines 
concomitantly. Among female and male adolescents, 30% received Tdap and 
meningococcal vaccines concomitantly.
Uptake of HPV vaccines
HPV vaccination among female adolescents increased in late spring, peaked in August, and 
decreased rapidly thereafter (black line in Figure 1, Panel A). Uptake was highest in June, 
July, and August, when healthcare providers delivered 38.7% of all vaccine doses (Table 2). 
This pattern reflects a substantial summer peak in HPV vaccination (p<.001) (Table 3). The 
RHL for this curve was 4.7, indicating that vaccination was about 5 times as frequent at the 
cycle’s peak as at its trough.
HPV vaccination in individual states (gray lines in Figure 1, Panel A) largely demonstrated 
the same summer peaks as in the U.S. overall, with summer peaks evident in each state (all 
p<.001) (Supplementary Table S1). The RHLs of states’ cycles varied from 2.5 in New 
Mexico to 98.2 in Nevada. This pattern of summer peaks in vaccination was evident in all 
study years (all p<.001) (Figure 2; Table 3). The RHLS of the peaks for HPV vaccine varied 
little from year to year, with no clear pattern, ranging from 4.5 in 2008 to 5.7 in 2010.
Uptake of other adolescent vaccines
Tdap booster and meningococcal vaccination (among female and male adolescents in the 
U.S.) largely reflected the same patterns as HPV vaccination, increasing in late spring, 
peaking in August, and decreasing rapidly thereafter (black lines in Figure 1, Panels B and 
C). Healthcare providers administered about 40% of all Tdap booster and meningococcal 
Moss et al. Page 5
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
vaccine doses during June, July, and August (40.2% and 41.1%, respectively) (Table 2). 
Each vaccination outcome demonstrated summer peaks across and within study years 
(Figure 2; Table 3) and within individual states (gray lines in Figure 1, Panels B and C; 
Supplementary Table S1) (all p<.001). The average RHL was 5.1 for Tdap booster and 10.1 
for meningococcal vaccine (Table 3). Tdap booster and meningococcal vaccination cycles 
were similar for female and male adolescents (Supplementary Figure S1).
Concomitant uptake of HPV vaccines with other adolescent vaccines
Concomitant vaccination largely reflected the same patterns as HPV and other adolescent 
vaccination individually, increasing in late spring, peaking in August, and decreasing rapidly 
thereafter (Supplementary Figure S2). Healthcare providers delivered about 40% of all 
concomitant vaccinations during June, July and August (HPV vaccine and Tdap booster: 
41.5%; HPV and meningococcal vaccines: 38.9%; Tdap booster and meningococcal 
vaccines: 40.9%; all three vaccines: 41.6%) (Table 2). Each concomitant vaccination 
outcome demonstrated summer peaks for the U.S., both across and within study years (all 
p<.001) (Supplementary Figure S2; Table 4). The average RHL was 4.6 for HPV vaccines 
and Tdap booster, 4.2 for HPV and meningococcal vaccines, 5.6 for Tdap booster and 
meningococcal vaccines, and 3.3 for all three vaccines.
Discussion
Cancer prevention efforts focused on HPV vaccination generally have not considered the 
possibility of seasonal variation in uptake. We found evidence of large summer peaks in 
uptake of HPV vaccines and its concomitant delivery with other adolescent vaccines. From 
2007 to 2012, healthcare providers administered around 40% of these vaccines during June, 
July, and August. HPV vaccination was about five times as high at the peak of the yearly 
cycle as compared to vaccination at the trough. This pattern of summer peaks for HPV 
vaccination (and uptake of other adolescent vaccines) occurred across years and within each 
state. Concomitant vaccination demonstrated similar summer peaks, although the overall 
prevalence was much lower, reflecting considerable missed opportunities. Leveraging these 
results could improve adolescent primary care and population health, particularly in 
increasing vaccination coverage and reducing the burden of HPV-associated cancers.
We found evidence of substantial missed opportunities for cancer prevention through HPV 
vaccination, especially alongside other adolescent vaccines. Overall, a minority of 
adolescents received HPV vaccine concomitantly with another adolescent vaccine, and 
many adolescents received Tdap booster or meningococcal vaccination without concomitant 
HPV vaccination. Increasing concomitant HPV vaccination could greatly improve national 
cancer prevention efforts. An opportunity for delivering catch-up doses of HPV vaccine that 
we did not study is concomitant delivery with booster doses of meningococcal vaccine in 
adolescents beginning at age 16 years (1). Additionally, given the temporal sequence of the 
HPV vaccine series, more research is needed on seasonal patterns in administration of all 
three HPV vaccine doses. Specifically, if adolescents who initiated HPV vaccination 
adhered to the recommended administration schedule for doses 2 and 3 (1–2 months and 6 
months after the first dose, respectively (1)), HPV vaccine completion may, for example, 
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have a secondary peak in February (6 months after the peak in initiation). A related point is 
that adolescents may have received doses 2 or 3 of HPV vaccine concomitantly with Tdap 
booster or meningococcal vaccine, and our current analysis of concomitant HPV vaccination 
would not have detected those incidences. Interventions that exploit trends in HPV 
vaccination (especially when delivered concomitantly) could improve coverage levels and 
offer greater cancer prevention to young people throughout their lifetimes.
Additional research is needed to understand how these vaccination cycles emerge. 
Vaccination requirements for school entry may encourage parents and adolescents to seek 
vaccination in the summer, especially in August, which coincides with the beginning of the 
school year in most areas of the U.S. (14). These policies could also explain some of the 
difference in magnitude of summer peaks for Tdap booster versus meningococcal vaccine: 
generally, states with requirements for the latter vaccine adopted them more recently. Their 
more recent implementation may exaggerate the observed summer peaks as parents newly 
rush to comply. Although national guidelines began recommending routine administration of 
Tdap booster and meningococcal vaccine in 2005, and HPV vaccines in female adolescents 
in 2006 (1), subsequent adoption of school entry requirements has been quite varied across 
states: As of 2012, 42 states had Tdap booster requirements, 14 had meningococcal 
vaccination requirements, and only 2 had HPV vaccination requirements (13). Despite the 
low prevalence of HPV vaccination requirements, we still observed summer peaks for that 
behavior across the U.S. This cyclical pattern could come about through carry-over effects 
of policies for Tdap or meningococcal vaccination (which are much more common), 
specifically through concomitant administration of a vaccine targeted by a school entry 
requirement along with HPV vaccine. Alternative explanations for the summer peaks 
include adolescents receiving vaccinations during physical exams required for summer 
camps and the relative ease of seeking adolescent vaccination when students are out of 
school.
Our national results extend the findings of two smaller descriptive studies. Sull and 
colleagues (14) used the New York City immunization information system (IIS) to measure 
monthly administration of adolescent vaccines among 11-year-old adolescents from 2005 to 
2013. Starting in 2007, they found small increases in uptake of HPV vaccine, and large 
increases in uptake of Tdap booster and meningococcal vaccine, in the summer compared to 
the rest of the year. Cullen and colleagues (15) used IIS data at 8 sentinel sites in the U.S. to 
analyze the weekly number of HPV vaccine doses administered among male and female 
adolescents aged 11–18 years. The authors reported relative increases in HPV vaccination 
during the summers of 2010–2012. Using nationally-representative data, we more precisely 
quantified the magnitude of summer peaks across time and for each state, tested their 
statistical significance, which has not been done previously, and examined cycles in 
concomitant vaccination.
Summer peaks in adolescent vaccination influence clinical practice for pediatric and family 
medicine physicians in at least three important ways. First, immunization quality 
improvement efforts are best suited to the spring months, because the relative decrease in 
vaccination during those times affords more organizational capacity to make structural 
changes in preparation for summer increases in vaccination (27,28). Second, summer peaks 
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in uptake of Tdap booster and meningococcal vaccine translate into increased opportunities 
for providers to recommend and administer HPV vaccine concomitantly. Given that a 
provider’s recommendation is the strongest and most consistent correlate of adolescent 
vaccination (29,30), recommending concomitant vaccination during immunization visits in 
the summer could bring about large increases in HPV vaccination coverage. Third, clinics 
require greater supplies of adolescent vaccines during the summer. Some clinicians have 
reported that HPV vaccine is expensive or burdensome to stock (31,32), but the results of 
the current study emphasize the importance of maintaining adequate supplies of adolescent 
vaccines during the summer in order to meet the demand for adolescent vaccination.
Additionally, these summer peaks in adolescent vaccination have implications for public 
health practice, research, and policy. Adolescent vaccination programs may serve as cues to 
action (33), but these effects typically decay (34); therefore, they may be especially fruitful 
if they occur in the summer or late spring in order to capitalize on the existing peaks (similar 
to the phenomenon of increasing advertising for consumer shopping during the winter 
holiday season (35)). National efforts to change the vaccination infrastructure (e.g., by 
introducing improved vaccine formulations (36) or improving functionality of reminder-
recall systems (37)) could focus on winter or spring months when demand is lower and 
disruptions to clinical operations would have the least impact on coverage. In addition, 
public health researchers should account for these cyclical patterns when conducting 
evaluations to avoid misattributing secular increases in coverage in the summer to 
promotion or intervention programs. This issue of potential confounding is of greatest 
concern for uncontrolled research study designs.
Study strengths include healthcare provider-verified vaccination data drawn from several 
years of a large, nationally-representative survey (18). Analyses employed an inferential 
statistical technique that supports inferences beyond descriptive approaches used previously 
(14,15). There are several study limitations: we could not distinguish between adolescents’ 
current states of residence (the unit of analysis in this study) and the states in which they 
received their vaccines. For adolescents who relocated during the time between vaccination 
and participation in NIS-Teen, the states in which they received vaccines may have been 
misattributed. However, given the similarity of the vaccination cycles evident across states 
and across years, the effect of this misattribution was likely minimal. In addition, in survey 
years 2008–2010, NIS-Teen staff contacted participants only through landline phones only, 
and in survey years 2011–2012, they contacted participants through landline and cell 
phones, which could introduce some systematic difference in samples across years (18). 
Because of small cell sizes, we were unable to evaluate summer peaks in 2012, and 
sparseness of data may have introduced noise into the estimates for the more recent years 
(especially for concomitant vaccination). As more data are accumulated, these patterns may 
become more robust and allow analysis of summer peaks for more recent years. Another 
potential limitation is that we examined cycles in HPV vaccination only among female 
adolescents, due to when recommendations for males became part of practice (19). 
However, our analyses of Tdap booster and meningococcal vaccination stratified by sex 
demonstrated very similar results, a finding that suggests that summer peaks in HPV 
vaccination could emerge among male adolescents, as well. Finally, in our analyses, we 
could not explore potential explanations for the relatively low levels of concomitant 
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vaccination (especially for HPV vaccine alongside Tdap boosters or meningococcal 
vaccines). Thus, we could not discern whether, for example, healthcare providers did not 
make recommendations or whether they made recommendations and parents declined 
concomitant vaccination. These two explanations would suggest different interventions to 
promote concomitant vaccination (i.e., provider-focused, parent-focused, or both), an 
important topic for future studies.
In summary, we found marked summer peaks in uptake of adolescent vaccines from 2007 to 
2012. For the U.S. and for individual states, vaccination increased substantially during the 
summer months. Healthcare providers administered about 40% of all adolescent vaccines 
during June, July, and August. These cycles have implications for both clinical practice 
(e.g., recommending concomitant vaccination during the summer) and public health (e.g., 
timing of vaccine promotion programs). Future studies should evaluate how cyclical patterns 
emerge and how promotion programs can harness these patterns to improve population-level 
coverage with adolescent vaccines and offer greater protection from HPV-attributable 
cancers.
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Figure 1. 
Summer peaks in adolescent vaccine uptake in the United States and individual states. 
Uptake standardized at 100 per month for 2007 to 2012. Source: National Immunization 
Survey-Teen, administered 2008 to 2012.
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Figure 2. 
Summer peaks in adolescent vaccine uptake in the United States, by year. Uptake 
standardized at 100 per month for 2007 to 2012. Source: National Immunization Survey-
Teen, administered 2008 to 2012.
Moss et al. Page 13
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moss et al. Page 14
Ta
bl
e 
1
D
es
cr
ip
tiv
e 
sta
tis
tic
s o
f p
ar
tic
ip
at
in
g 
pa
re
nt
s a
nd
 th
ei
r a
do
le
sc
en
t c
hi
ld
re
n 
(so
urc
e: 
Na
tio
na
l I
mm
un
iza
tio
n S
urv
ey
-T
ee
n, 
ad
mi
nis
ter
ed
 20
08
 to
 20
12
).
To
ta
l S
am
pl
e
Fe
m
al
e
M
al
e
n
(%
)
n
(%
)
n
(%
)
To
ta
l
70
,1
44
35
,7
74
52
.1
%
34
,3
70
47
.9
%
Su
rv
ey
 y
ea
r
 
 
 
 
20
08
7,
51
9
12
.5
%
4,
36
5
13
.8
%
3,
15
4
11
.0
%
 
 
 
 
20
09
12
,1
18
17
.4
%
6,
51
6
18
.2
%
5,
60
2
16
.4
%
 
 
 
 
20
10
14
,1
11
20
.7
%
7,
20
9
20
.5
%
6,
90
2
20
.8
%
 
 
 
 
20
11
19
,4
81
23
.9
%
9,
58
4
23
.1
%
9,
89
7
24
.9
%
 
 
 
 
20
12
16
,9
15
25
.5
%
8,
10
0
24
.3
%
8,
81
5
26
.9
%
Ad
ol
es
ce
nt
 ch
ar
ac
te
ris
tic
s
A
ge
 
 
 
 
13
15
,3
02
21
.1
%
7,
51
9
20
.4
%
7,
78
3
21
.9
%
 
 
 
 
14
15
,3
23
21
.0
%
7,
59
3
20
.4
%
7,
73
0
21
.6
%
 
 
 
 
15
14
,6
33
22
.0
%
7,
48
1
22
.0
%
7,
15
2
22
.0
%
 
 
 
 
16
13
,5
66
19
.6
%
7,
09
2
19
.9
%
6,
47
4
19
.2
%
 
 
 
 
17
11
,3
20
16
.4
%
6,
08
9
17
.3
%
5,
23
1
15
.3
%
R
ac
e/
et
hn
ic
ity
 
 
 
 
H
isp
an
ic
9,
50
2
20
.5
%
4,
87
5
20
.6
%
4,
62
7
20
.3
%
 
 
 
 
N
on
-H
isp
an
ic
 w
hi
te
47
,6
91
57
.2
%
24
,2
39
56
.9
%
23
,4
52
57
.6
%
 
 
 
 
N
on
-H
isp
an
ic
 b
la
ck
7,
07
9
14
.4
%
3,
60
4
14
.4
%
3,
47
5
14
.3
%
 
 
 
 
O
th
er
5,
87
2
8.
0%
3,
05
6
8.
1%
2,
81
6
7.
8%
Pr
iv
at
e 
he
al
th
 in
su
ra
nc
e
 
 
 
 
Y
es
47
,8
46
60
.7
%
24
,4
74
61
.0
%
23
,3
72
60
.3
%
 
 
 
 
N
o
21
,9
25
39
.3
%
11
,1
14
39
.0
%
10
,8
11
39
.7
%
Pr
ev
en
tiv
e 
vi
sit
 in
 th
e 
la
st 
ye
ar
 
 
 
 
Y
es
61
,9
88
87
.5
%
31
,6
92
88
.0
%
30
,9
26
87
.0
%
 
 
 
 
N
o
8,
15
6
12
.5
%
4,
08
2
12
.0
%
4,
07
4
13
.0
%
Pa
re
nt
 c
ha
ra
ct
er
ist
ic
s
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moss et al. Page 15
To
ta
l S
am
pl
e
Fe
m
al
e
M
al
e
n
(%
)
n
(%
)
n
(%
)
R
el
at
io
ns
hi
p 
of
 re
sp
on
de
nt
 to
 a
do
le
sc
en
t
 
 
 
 
M
ot
he
r/f
em
al
e 
gu
ar
di
an
55
,8
52
77
.1
%
28
,7
39
78
.5
%
27
,1
13
75
.5
%
 
 
 
 
Fa
th
er
/m
al
e 
gu
ar
di
an
11
,2
23
17
.0
%
5,
46
9
15
.7
%
5,
75
4
18
.4
%
 
 
 
 
O
th
er
3,
06
9
5.
9%
1,
56
6
5.
8%
1,
50
3
6.
1%
M
ot
he
r's
 e
du
ca
tio
n 
le
ve
l
 
 
 
 
Le
ss
 th
an
 h
ig
h 
sc
ho
ol
6,
48
6
13
.8
%
3,
35
5
13
.9
%
3,
13
1
13
.7
%
 
 
 
 
H
ig
h 
sc
ho
ol
13
,2
39
25
.2
%
6,
66
5
24
.7
%
6,
57
4
25
.7
%
 
 
 
 
So
m
e 
po
st-
hi
gh
 sc
ho
ol
19
,4
66
25
.6
%
10
,0
29
26
.2
%
9,
43
7
24
.9
%
 
 
 
 
Co
lle
ge
 g
ra
du
at
e
30
,9
53
35
.4
%
15
,7
25
35
.2
%
15
,2
28
35
.6
%
H
ou
se
ho
ld
 ch
ar
ac
te
ris
tic
s
Po
ve
rty
 st
at
us
 
 
 
 
B
el
ow
 p
ov
er
ty
 le
ve
l
9,
90
2
20
.7
%
5,
10
1
21
.0
%
4,
80
1
20
.3
%
 
 
 
 
A
bo
ve
 p
ov
er
ty
 le
ve
l
57
,5
84
74
.3
%
29
,3
47
74
.0
%
28
,2
37
74
.6
%
 
 
 
 
U
nk
no
w
n
2,
65
8
5.
1%
1,
32
6
5.
0%
1,
33
2
5.
1%
U
rb
an
ic
ity
 
 
 
 
N
on
-m
et
ro
po
lit
an
13
,0
76
14
.3
%
6,
80
7
14
.5
%
6,
26
9
14
.0
%
 
 
 
 
M
et
ro
po
lit
an
50
,3
73
85
.7
%
25
,7
27
85
.5
%
24
,6
46
86
.0
%
Ce
ns
us
 re
gi
on
 
 
 
 
N
or
th
ea
st
15
,3
56
19
.6
%
7,
83
6
19
.7
%
7,
52
0
19
.5
%
 
 
 
 
M
id
w
es
t
15
,5
24
21
.5
%
8,
00
1
21
.4
%
7,
52
3
21
.6
%
 
 
 
 
So
ut
h
23
,8
45
34
.5
%
12
,1
07
34
.3
%
11
,7
38
34
.7
%
 
 
 
 
W
es
t
15
,4
19
24
.4
%
7,
83
0
24
.6
%
7,
58
9
24
.1
%
No
te
.
 
Fr
eq
ue
nc
ie
s a
re
 u
nw
ei
gh
te
d;
 p
ro
po
rti
on
s a
re
 w
ei
gh
te
d.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moss et al. Page 16
Ta
bl
e 
2
A
do
le
sc
en
t v
ac
ci
na
tio
n 
co
ve
ra
ge
 a
nd
 v
ac
ci
ne
 d
os
es
 a
dm
in
ist
er
ed
 p
er
 m
on
th
 in
 th
e 
U
ni
te
d 
St
at
es
, 2
00
7–
20
12
 (s
ou
rce
: N
ati
on
al 
Im
mu
niz
ati
on
 Su
rve
y-
Te
en
, a
dm
in
ist
er
ed
 2
00
8 
to
 2
01
2;
 n
=
70
,1
44
 a
do
le
sc
en
ts)
.
Si
ng
le
 v
ac
ci
na
tio
n
C
on
co
m
ita
nt
 v
ac
ci
na
tio
n
H
PV
1
Td
ap
M
en
g
H
PV
1  
a
n
d
Td
ap
H
PV
1  
a
n
d
M
en
g
Td
ap
 a
nd
M
en
g
A
ll 
th
re
e
O
ve
ra
ll 
co
ve
ra
ge
47
.9
%
65
.5
%
58
.9
%
15
.5
%
21
.6
%
30
.3
%
7.
9%
M
on
th
 
 
 
 
Ja
nu
ar
y
8.
0%
6.
7%
6.
2%
10
.2
%
7.
1%
6.
3%
8.
9%
 
 
 
 
Fe
br
ua
ry
7.
6%
6.
3%
7.
2%
5.
3%
7.
2%
6.
0%
5.
7%
 
 
 
 
M
ar
ch
7.
2%
7.
8%
7.
6%
6.
9%
7.
8%
8.
2%
6.
9%
 
 
 
 
A
pr
il
8.
0%
8.
1%
7.
8%
8.
2%
8.
9%
8.
4%
9.
3%
 
 
 
 
M
ay
6.
8%
8.
6%
7.
4%
7.
8%
7.
2%
8.
2%
8.
5%
 
 
 
 
Ju
ne
10
.2
%
9.
2%
10
.0
%
8.
5%
8.
5%
9.
1%
8.
0%
 
 
 
 
Ju
ly
12
.6
%
12
.0
%
13
.1
%
13
.0
%
12
.8
%
12
.9
%
13
.3
%
 
 
 
 
A
ug
us
t
15
.9
%
19
.0
%
18
.0
%
20
.0
%
17
.6
%
18
.9
%
20
.3
%
 
 
 
 
Se
pt
em
be
r
7.
4%
8.
2%
7.
9%
7.
7%
9.
0%
7.
8%
6.
2%
 
 
 
 
O
ct
ob
er
7.
2%
6.
5%
6.
4%
6.
1%
6.
1%
6.
8%
6.
5%
 
 
 
 
N
ov
em
be
r
5.
6%
4.
4%
5.
2%
3.
9%
5.
1%
4.
4%
4.
2%
 
 
 
 
D
ec
em
be
r
3.
5%
3.
2%
3.
4%
2.
4%
2.
7%
2.
9%
2.
2%
No
te
.
 
Pr
op
or
tio
ns
 a
re
 w
ei
gh
te
d.
 S
ta
tis
tic
s f
or
 H
PV
, H
PV
 a
nd
 T
da
p,
 H
PV
 a
nd
 M
en
g,
 a
nd
 A
ll 
th
re
e 
va
cc
in
es
 a
re
 fo
r f
em
al
e 
ad
ol
es
ce
nt
s o
nl
y.
 H
PV
=h
um
an
 p
ap
ill
om
av
iru
s v
ac
ci
ne
; T
da
p=
te
ta
nu
s, 
di
ph
th
er
ia
, 
an
d 
pe
rtu
ss
is 
bo
os
te
r; 
M
en
g=
m
en
in
go
co
cc
al
 v
ac
ci
ne
.
1 U
pt
ak
e 
of
 fi
rs
t d
os
e 
am
on
g 
fe
m
al
e 
ad
ol
es
ce
nt
s o
nl
y.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moss et al. Page 17
Ta
bl
e 
3
M
ag
ni
tu
de
 o
f s
um
m
er
 p
ea
ks
 in
 a
do
le
sc
en
t v
ac
ci
na
tio
n 
in
 th
e 
U
ni
te
d 
St
at
es
 (s
ou
rce
: N
ati
on
al 
Im
mu
niz
ati
on
 Su
rve
y-T
ee
n, 
ad
mi
nis
ter
ed
 20
08
 to
 20
12
; 
n
=
70
,1
44
 a
do
le
sc
en
ts)
. H
PV
1
Td
ap
M
en
g
T
m
a
gn
itu
de
(R
HL
[va
r])
T
m
a
gn
itu
de
(R
HL
[va
r])
T
m
a
gn
itu
de
(R
HL
[va
r])
Co
m
bi
ne
d 
ye
ar
s
5,
03
7,
75
2*
4.
7
(0.
01
)
12
,1
73
,7
02
*
5.
1
(0.
01
)
19
,0
67
,7
76
*
10
.1
(0.
01
)
Y
ea
r
20
07
2,
14
5,
02
7*
5.
7
(0.
01
)
3,
55
2,
04
8*
4.
6
(0.
01
)
4,
79
3,
36
5*
7.
5
(0.
01
)
20
08
1,
34
9,
45
2*
4.
5
(0.
01
)
3,
09
9,
10
0*
4.
5
(0.
01
)
5,
33
3,
91
9*
8.
3
(0.
01
)
20
09
87
6,
75
6*
5.
3
(0.
01
)
2,
45
8,
18
2*
5.
0
(0.
01
)
3,
87
3,
03
7*
9.
1
(0.
01
)
20
10
56
3,
74
4*
5.
7
(0.
01
)
1,
65
4,
17
8*
5.
7
(0.
01
)
2,
36
6,
46
1*
10
.5
(0.
01
)
20
11
34
1,
77
1*
4.
8
(0.
01
)
86
8,
27
5*
6.
6
(0.
01
)
1,
35
4,
80
8*
21
.2
(0.
01
)
No
te
.
 
H
PV
=h
um
an
 p
ap
ill
om
av
iru
s v
ac
ci
ne
; T
da
p=
te
ta
nu
s, 
di
ph
th
er
ia
, a
nd
 p
er
tu
ss
is 
bo
os
te
r; 
M
en
g=
m
en
in
go
co
cc
al
 v
ac
ci
ne
; T
=
Ed
w
ar
ds
 T
 st
at
ist
ic
; R
H
L=
ra
tio
 o
f h
ig
he
st 
to
 lo
w
es
t v
ac
ci
na
tio
n;
 
v
ar
=
v
ar
ia
nc
e.
*
p<
.0
01
.
1 U
pt
ak
e 
of
 fi
rs
t d
os
e 
am
on
g 
fe
m
al
e 
ad
ol
es
ce
nt
s o
nl
y.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moss et al. Page 18
Ta
bl
e 
4
M
ag
ni
tu
de
 o
f s
um
m
er
 p
ea
ks
 in
 c
on
co
m
ita
nt
 a
do
le
sc
en
t v
ac
ci
na
tio
n 
in
 th
e 
U
ni
te
d 
St
at
es
 (s
ou
rce
: N
ati
on
al 
Im
mu
niz
ati
on
 Su
rve
y-T
ee
n, 
ad
mi
nis
ter
ed
 20
08
 
to
 2
01
2;
 n
=
70
,1
44
 a
do
le
sc
en
ts)
.
H
PV
1  
a
n
d 
Td
ap
H
PV
1  
a
n
d 
M
en
g
Td
ap
 a
nd
 M
en
g
A
ll 
th
re
e
T
m
a
gn
itu
de
(R
HL
[va
r])
T
m
a
gn
itu
de
(R
HL
[va
r])
T
m
a
gn
itu
de
(R
HL
[va
r])
T
m
a
gn
itu
de
(R
HL
[va
r])
Co
m
bi
ne
d
Y
ea
rs
1,
50
4,
76
6*
4.
6
(0.
01
)
1,
91
5,
59
9*
4.
2
(0.
01
)
6,
84
8,
77
2*
5.
6
(0.
01
)
74
4,
32
0*
3.
3
(0.
01
)
Y
ea
r
20
07
64
0,
47
1*
6.
2
(0.
01
)
76
1,
52
2*
4.
8
(0.
01
)
1,
64
1,
64
9*
5.
1
(0.
01
)
28
8,
10
3*
4.
5
(0.
01
)
20
08
37
3,
94
7*
4.
0
(0.
01
)
61
9,
11
9*
4.
3
(0.
01
)
1,
75
6,
69
4*
4.
7
(0.
01
)
19
5,
48
4*
3.
1
(0.
01
)
20
09
39
5,
75
3*
7.
2
(0.
01
)
48
7,
68
2*
6.
4
(0.
01
)
1,
42
0,
71
8*
4.
8
(0.
01
)
21
3,
42
5*
4.
2
(0.
01
)
20
10
28
0,
42
1*
10
.4
(0.
01
)
24
3,
70
9*
5.
8
(0.
01
)
1,
15
2,
33
3*
7.
5
(0.
01
)
16
0,
42
4*
5.
6
(0.
01
)
20
11
13
5,
13
5*
8.
3
(0.
01
)
12
8,
36
7*
5.
2
(0.
01
)
48
2,
16
1*
6.
9
(0.
01
)
38
,7
52
*
3.
3
(0.
01
)
No
te
.
 
H
PV
=h
um
an
 p
ap
ill
om
av
iru
s v
ac
ci
ne
; T
da
p=
te
ta
nu
s, 
di
ph
th
er
ia
, a
nd
 p
er
tu
ss
is 
bo
os
te
r; 
M
en
g=
m
en
in
go
co
cc
al
 v
ac
ci
ne
; T
=
Ed
w
ar
ds
 T
 st
at
ist
ic
; R
H
L=
ra
tio
 o
f h
ig
he
st 
to
 lo
w
es
t v
ac
ci
na
tio
n;
 
v
ar
=
v
ar
ia
nc
e.
*
p<
.0
01
.
1 U
pt
ak
e 
of
 fi
rs
t d
os
e 
am
on
g 
fe
m
al
e 
ad
ol
es
ce
nt
s o
nl
y.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.
